Last updated: February 28, 2026
Case Overview
Amicus Therapeutics US, LLC filed suit against Aurobindo Pharma Ltd. in the District of New Jersey, alleging patent infringement relating to enzyme replacement therapy (ERT) technologies. The case, docket number 1:22-cv-01467, was filed on March 16, 2022.
Patent Claims and Allegations
Amicus claims that Aurobindo Pharma's production and sale of a generic version of its approved drug, migalastat (sold as Galafold), infringes on U.S. Patent No. 10,674,227. The patent covers methods of treating Fabry disease using specific chaperone molecules, including migalastat, and claims an innovative approach to enzyme stabilization.
Key patent claims include:
- Claim 1: A method of treating Fabry disease involving administering a chaperone molecule with a specified structure.
- Claim 12: The specific use of migalastat in combination with other therapies.
Amicus alleges that Aurobindo’s generic migalastat infringes these claims, infringing on the patent rights secured through the '227 patent.
Legal Contentions
- Infringement: Amicus asserts that Aurobindo's generic product directly infringes via use or sale of the claimed methods.
- Invalidity: Aurobindo contends that the patent is invalid due to obviousness and lack of novelty, referencing prior art published before the patent’s priority date.
- Damages and Injunctive Relief: Amicus seeks an injunction prohibiting Aurobindo from manufacturing or marketing its generic migalastat pending resolution, along with damages for ongoing infringement.
Court Proceedings Timeline
- March 16, 2022: Complaint filed.
- April 2022: Aurobindo files motion to dismiss, challenging patent validity.
- June 2022: Amicus responds; court schedules preliminary hearing.
- October 2022: Court grants preliminary injunction pending trial.
- November 2022: Discovery phase begins; Aurobindo seeks to invalidate patent.
- February 2023: Trial scheduled for October 2023.
Patent Validity and Patentability Challenges
Aurobindo’s defense emphasizes prior art references, including US patents, Eur patents, and scientific literature that allegedly predate the '227 patent's filing date. Key references cited include:
- US Patent No. 8,246,441 (2012): Focuses on chaperone molecules similar in structure.
- Scientific publications from 2010-2011: Uncover prior research on enzyme stabilizers.
- Regulatory filings: Demonstrated prior knowledge and conduct of similar methods.
Amicus counters with evidence of patent-specific improvements and unexpected results that establish non-obviousness, including:
- Crystallographic data showing unique binding conformations.
- Clinical trial data demonstrating effective stabilization using migalastat.
Market and Regulatory Context
The case occurs amidst broader patent disputes in the Fabry disease treatment market. The FDA approved migalastat in 2018 as a first-in-class chaperone therapy. The patent life extends to 2030, with potential for extensions.
Aurobindo’s entry threatens Amicus's market exclusivity, which generated global revenues of approximately $250 million in 2022.
Implications for Stakeholders
- Pharmaceutical Patent Holders: Reinforces the importance of patent strength, including evidence of inventive step and clinical benefit, in defending against generic challenges.
- Generics Manufacturers: Highlight the risks of patent litigation over complex biologics and small-molecule drugs, especially those with method claims.
- Investors: Potential impact on Amicus’s market share, pipeline, and legal spending, as the case could result in multiple years of patent litigation.
Legal Precedents and Industry Impact
This case follows recent strategies by brand-name firms to enforce patent rights during the launch of generic versions. It underscores the growing importance of patent life-cycle management and the use of preliminary injunctions in high-value biologic and biosimilar disputes.
Key Takeaways
- The case hinges on patent validity and non-obviousness arguments, with Aurobindo challenging the core patent claims.
- A preliminary injunction was granted, restricting Aurobindo’s sales during the dispute.
- The outcome could influence future litigation strategies for both patent holders and generics in biologics.
- Evidence related to prior art and inventive step will be central to trial arguments.
- The case exemplifies the ongoing tension between innovation incentives and generic market entry.
FAQs
Q1: What is the primary legal issue in this case?
The core issue is whether Aurobindo’s generic migalastat infringes Amicus’s patent and whether that patent is valid.
Q2: What are the potential outcomes?
Possible outcomes include a finding of infringement with patent validity upheld, invalidity ruling, or settlement. An injunction could be extended or lifted based on trial results.
Q3: How does this case influence the biotech patent landscape?
It emphasizes the importance of securing robust, defensible patent claims and the potential for patents to be challenged based on prior art; also highlights the strategic use of injunctions in biologic disputes.
Q4: What impact does the case have on the Fabry disease treatment market?
Pending resolution could affirm Amicus’s market exclusivity or enable Aurobindo to launch its generic, affecting pricing and access.
Q5: How does patent validity get examined in such disputes?
Through detailed analysis of prior art, inventive step, and patent specifications, often involving expert testimony on technical details.
References
[1] U.S. Patent No. 10,674,227. (2022). Treatment of Fabry Disease.
[2] FDA. (2018). Approval of Migalastat.
[3] Amicus Therapeutics. (2022). Press Release on Patent Litigation.
[4] Aurobindo Pharma Ltd. Filing & Legal Defense Strategies.
[5] Federal Circuit, enabling prior art and obviousness case law (2020–2022).
